Cite
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
MLA
Liebers, Nora, et al. “Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas.” Blood Advances, vol. 5, no. 13, July 2021, pp. 2707–16. EBSCOhost, https://doi.org/10.1182/bloodadvances.2020004155.
APA
Liebers, N., Duell, J., Fitzgerald, D., Kerkhoff, A., Noerenberg, D., Kaebisch, E., Acker, F., Fuhrmann, S., Leng, C., Welslau, M., Chemnitz, J., Middeke, J.-M., Weber, T., Holtick, U., Trappe, R., Pfannes, R., Liersch, R., Spoer, C., Fuxius, S., … Dietrich, S. (2021). Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Advances, 5(13), 2707–2716. https://doi.org/10.1182/bloodadvances.2020004155
Chicago
Liebers, Nora, Johannes Duell, Donnacha Fitzgerald, Andrea Kerkhoff, Daniel Noerenberg, Eva Kaebisch, Fabian Acker, et al. 2021. “Polatuzumab Vedotin as a Salvage and Bridging Treatment in Relapsed or Refractory Large B-Cell Lymphomas.” Blood Advances 5 (13): 2707–16. doi:10.1182/bloodadvances.2020004155.